Title (required) First Name (required) Last Name (required)				
OME DAME Laurie Grand	* * *		001	STN NO
Organization STOP- Sale Tables Our Priority	****	SIHL	4	Š
Stakeholder Group stakeholder group you represent	* ** **	THIS FILE :	634	8
Consumer Consumer Group Health Professional Industry Association Other	* *	S SI MOU		
Center ✓ the center/product area your comments address	; `	STILL	3 0	ABBR
☐ Center for Biologics Evaluation and Research ☐ Center for Devices and Radiological Health ☐ Center for Veterinary Medicine ☐ Office of Regulatory Affairs ☐ FDA General	*********************	COMMUNICATION(S) O		ë.
Questions to Stakeholders) OCCURRED. RY. YOU MAY	8883614011	STATION
Please check the box next to the stakeholder question/s from the March 22, 1999, Federal Register notice which your question/comment addresses.	n oldne-	ED. MAY RETRY	011	ND ME
What actions do you propose the Agency take to expand FDA's capability to incorporate state-of-the-art science into its risk-based decision-making?	∩SI^	RY R		TEL. NO
2. What actions do you propose to facilitate the exchange and integration of scientific information to better enable FDA to meet its public health responsibilities throughout a product's life cycle?	•			•
3. What actions do you propose for educating the public about the concept of balancing risks against benefits in public health decision-making?	۱ *	DELETE -	988	PAGES
4. What actions do you propose to enable FDA and its product centers to focus resources on areas of greatest risk to the public health?	* * * *	-PRO	000/001	S
5. What additional actions do you propose for enhancing communication processes that allow for ongoing feedback and/or evaluation of our modernization efforts?	1	BY EDIT FI		Ž
□ 6. Additional Comments on FDA Modernization Efforts.		FILE	00:00°00	DURATION
	415		ā	모
YOUR COMMENT/QUESTION	ω [2	MODE.		
We will be to see the more up they exped to want you have done on here done	80			
TDA seems to have instituted processes for including consumers in drug-related advisory committees, and for ensuring that consumers receive warning information about drugs. Why do you not apply similar processes to foods that have been identified as being repeatedly hazardows? * Consumers need this information quickly at the point of	6452-	1		
committees, and to ensuring that consumers receive warring information about drugs.	* *			
Why do you not apply similar processes to toods that have been identified as being	****			
repeatedly hazardous! I Consumers need this information quickly at the point of	* * *			
purchase,	-			

START=APR-28 11:01

END=APR-28 11:22

MODE = MEMORY TRANSMISSION

FILE NO. = 048

ABBR NO.

STATION NAME/TEL.NO.

PAGES

DURATION